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What is an E. coli BG and which are their applications to this vaccine design?  
 
BGs are generated by the outer and inner membranes of E. coli being lysate by the E- enzyme, 
which forms a tunnel that allows the bacterial cytoplasmic content go outside. 
BGs work as carriers for a S. aureus virulence protein which is exposed in their outer membrane, 
FnBPA in this case. This structure will merge the bacterium natural infection. 
o Fibronectin binding protein A is a S. aureus protein 
which allows the bacterium to adhere to hosts and enter 
inside them, acting as a bridge.  
o FnBPA is involved in adherence to mammalian cells and 
in the infective process. 
o In Helicobacter pylori a BG-based vaccine had positive 
results using a protein with a 70% of identity with FnBPA. 
This was determined by a BLAST analysis. 
 
 
 
 
 
 
Materials and Methods 
Plasmid constructions 
Immunogenic assays 
Conclusions 
Vaccine production 
pHS64FnbPA: 38 aminoacids of FnBPA 
were cloned into plasmid pHS64. 
FnBPA was flanked between two 
ompA (outer membrane protein A) 
sequences. This allows the expression 
of the FnBPA in the E. coli outer 
membrane. This construction is under 
a PTAC promoter control. 
1. Introduction 
This poster is a Research Project Proposal for the design of a vaccine 
against Staphylococcus aureus. 
S. aureus is a gram-positive bacterium, the most common cause of 
nosocomial infections. It is also resistant to most of the antibiotics. 
The design of an effective vaccine would reduce the amount of 
infected people, specially in hospitals. 
2. Hypothesis 
Escherichia coli’s Bacterial Ghosts (BG) that 
express Fibronectin-binding protein A 
(FnBPA) in their surface will generate 
effective immune response against S. aureus 
infections.  
Positive evidences were shown in a BG-
based vaccine against Helicobacter pylori. 
 
 
3. Objectives 
To design a vaccine against S. aureus that:  
 
a)  Stimulates both cellular and humoral immune 
response. 
b) Avoids secondary responses against the 
vaccination process. 
Why FnBPA? 
1.  E. coli is cultured in LB media at 28ºC and transformed with pHS64FnBPA and pLysE 
plasmids by electroporation. CFUs are counted. 
2.  pHS64FnbPA induction adding 0.5 mM IPTG: ompA-FnBPA38-ompA insertion in E. coli 
outer membrane. 
3. pLysE induction raising temperature to 42ºC: tunnel formation. 
4. Antibiotic addition to inactivate E. coli after transformation and after 1h, CFUs 
recount. 
5. SDS-PAGE and Western Blot assay to determine if FnBPA is into the outer membrane 
pLysE: cassette with lysis E gene was 
cloned into plasmid pBBR1MCS5 with a 
replication origin and a gentamicin 
resistance. Its induction is under 
temperature regulation. 
28 weeks-old females BALB/c mice were immunized via subcutaneous injection (15 ♀ for each group)  
109 BGs in 100 µl 
NaCl without 
expressing FnbPA 
109 BGs in 100 µl NaCl 
expressing FnbPA 
1µg FnBPA in 
100µl NaCl 
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After first immunization, FnBPA specific Abs are expected to be detected in both sample injection and positive control in the two ELISA test. If there is no presence, the boost 
dose (half of the initial dose) is supposed to solve this problem.  FnBPA-Abs presence in negative control should to be zero. 
TCD4 and TCD8 lymphocytes are also supposed to be detected in immunized mice using flow cytometry. The same response as in ELISA test has to be detected in negative 
control. 
The CFUs concentration in the surveillance assay is supposed to kill the 80% of mice not immunized. Control and treated mice with the BGs carrying FnBPA are supposed to 
have higher surveillance rates than negative control. The best situation will be a 100% surveillance with the sample dose.   
If this strategy works in mice it should be a good vaccine to be tested in human patients. 
   
Fig 1: E. coli  bacterial ghost characterized 
by Scanning Electron Microscope (SEM).  
June 2015. 
All images are either self-made or Creative 
Commons. 
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Fig 2: Bacterial ghost final structure expressing FnBPA 
into the outer membrane. 
2 days 
Blood samples were 
analyzed by ELISA test to 
determine  antibodies (Ab)  
presence. 
14 days 
Boost dose to 5 
mice of each group. 
Second ELISA test 
 
21 days 5·10
7 CFUs injected to 
all mice  to do a 
surveillance assay 
Survivor mice 
8 weeks 
Mice were sacrificed.  
Non-survivor mice 
Spleens were lysed and stimulated with 30µg of sonicated S. 
aureus (+ negative control with concavalin A).  
The presence of TCD4/8 was analyzed by flow cytometry. 
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